Modality
Peptide
MOA
HPK1i
Target
PD-L1
Pathway
PI3K/AKT
CRCMDD
Development Pipeline
Preclinical
May 2018
→ Mar 2027
PreclinicalCurrent
NCT05000551
45 pts·MDD
2018-05→2027-03·Completed
NCT05795088
281 pts·MDD
2025-05→2025-10·Completed
326 total pts1 indication
Phase 1
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2025-10-225mo agoInterim· MDD
2027-03-1111mo awayInterim· MDD
Trial Timeline
Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2
Preclinical
Complet…
Preclinical
Complet…
Catalysts
Interim
2025-10-22 · 5mo ago
MDD
Interim
2027-03-11 · 11mo away
MDD
Completed|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT05000551 | Preclinical | MDD | Completed | 45 | Biomarker |
| NCT05795088 | Preclinical | MDD | Completed | 281 | EFS |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-1944 | Pfizer | NDA/BLA | APOC3 | |
| NVS-6974 | Novartis | Preclinical | CD19 | |
| ABB-7516 | AbbVie | Phase 3 | PD-L1 | |
| Olpatinib | GSK | Preclinical | PD-L1 | |
| BAY-3684 | Bayer | Approved | PD-L1 | |
| Bemanesiran | BioNTech | Phase 3 | PLK4 | |
| BII-5240 | Biogen | Phase 2/3 | MALT1 | |
| Semasacituzumab | Illumina | Phase 3 | Nectin-4 | |
| Polatuximab | Nuvalent | Approved | PD-L1 | |
| VKT-6548 | Viking Therapeutics | Phase 2/3 | PD-L1 |